Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd. (BWAY) generates a steady flow of news centered on its Deep TMS™ neurostimulation technology, regulatory developments, clinical research, and financial performance. As a company focused on noninvasive brain stimulation for mental health disorders, BrainsWay frequently announces updates related to major depressive disorder, obsessive-compulsive disorder, smoking addiction, and emerging indications such as Alcohol Use Disorder.
News items for BrainsWay often cover FDA clearances and label expansions, including accelerated Deep TMS protocols for MDD and indications that extend treatment to adolescent patients aged 15 to 21. The company also reports on payer coverage decisions, such as new or expanded medical policies from insurers that reimburse Deep TMS depression therapy for adults and adolescents, and coverage of its SWIFT™ accelerated protocol. These updates provide insight into how access to Deep TMS is evolving across different patient populations and geographies.
Investors following BWAY can also expect clinical research and grant-related announcements, including NIH-funded studies evaluating accelerated Deep TMS protocols for Alcohol Use Disorder and stimulant use disorders, as well as company-sponsored trials using the Deep TMS 360™ multichannel system. In addition, BrainsWay issues news on strategic investments, such as its minority-stake investment in Neurolief and stakes in mental health providers, and on financial results that highlight revenue trends, installed base growth, and multi-year customer agreements.
The BrainsWay news page on Stock Titan aggregates these updates so readers can track regulatory milestones, payer coverage changes, clinical trial progress, strategic partnerships, and quarterly financial disclosures related to BWAY stock. This makes it a useful reference for monitoring how the company’s Deep TMS platform and broader neuromodulation strategy are developing over time.
BrainsWay, a leader in advanced non-invasive treatments for brain disorders, announced that CEO Christopher von Jako will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022. The event will take place at the Lotte Palace Hotel in New York City. The fireside chat is scheduled for 7:00 a.m. ET. BrainsWay is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, which is FDA cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
BrainsWay Ltd. has received FDA 510(k) clearance for its Deep TMS™ H7 Coil, marking the company’s 9th FDA approval. This new clearance allows treatment of adults with major depressive disorder and anxious depression, enhancing options for treatment-resistant patients. A multicenter trial with 144 subjects demonstrated the H7 Coil’s efficacy similar to the existing H1 Coil. This advancement solidifies BrainsWay's commitment to personalized medicine and expands its non-pharmaceutical treatment arsenal.
BrainsWay Ltd. (NASDAQ: BWAY) reported a 14% revenue increase in Q2 2022, totaling $8.0 million, marking its eighth consecutive quarter of growth. The installed base for Deep TMS™ systems rose 22% year-over-year to 829 units. Reimbursement progress included a positive coverage policy from Highmark BCBS for OCD treatment, enhancing eligibility to nearly 70 million lives. However, gross margin decreased to 73% from 81% due to inventory costs and increased international sales. Operating loss widened to $2.0 million compared to $1.5 million in the prior year.
Burlington, Mass. and Jerusalem, July 27, 2022 - BrainsWay Ltd. (BWAY) will report its second quarter financial results before U.S. markets open on August 10, 2022. A conference call will follow at 8:30 AM ET to discuss these results and update on business operations. BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. For further details and to access the call, visit their official website.
BrainsWay Ltd. (NASDAQ: BWAY) has achieved a significant milestone with the Israeli Ministry of Health approving its Deep TMS™ treatment for depression, now included in Israel's health basket of essential medical services. This means qualifying patients over 21, who have not responded to prior antidepressants, can receive up to 40 sessions free of charge. Dr. Christopher von Jako emphasized the importance of access to this Israeli innovation, as the company aims to expand insurance coverage globally, focusing on improving mental health treatment accessibility.
BrainsWay Ltd. announces positive coverage from Highmark BCBS for its Deep TMS™ treatment of obsessive-compulsive disorder (OCD), effective May 2, 2022. This coverage benefits 6.8 million members across New York, Pennsylvania, West Virginia, and Delaware. With existing coverage from Health Care Service Corporation, nearly 70 million lives are now eligible for Deep TMS OCD treatment. BrainsWay remains the only TMS company with FDA clearance for OCD, backed by positive clinical data. The firm aims to enhance reimbursement for Deep TMS through continued engagement with major payors.
BrainsWay Ltd. (NASDAQ: BWAY) reported a 30% year-over-year revenue growth in Q1 2022, achieving total revenues of $8.0 million, up from $6.1 million in Q1 2021. The company's gross margin improved to 77%, while operating expenses increased to $7.6 million, leading to an operating loss of $1.5 million. Despite operational challenges due to the Omicron surge, the firm saw a 21% increase in its Deep TMS installed base, totaling 790 systems as of March 31, 2022. Leadership changes were also made to support long-term growth.
BrainsWay Ltd. has appointed Eric Hirt as Vice President of U.S. Sales, bringing over 20 years of medical device sales and marketing experience. Hirt's role will focus on promoting the company's Deep Transcranial Magnetic Stimulation (Deep TMS™) system, aimed at expanding its market presence and increasing demand for its FDA-cleared treatment indications. The company highlights its commitment to advancing mental health solutions through innovative technology, backed by robust clinical evidence.
BrainsWay Ltd. (NASDAQ: BWAY) will showcase its Deep TMS™ technology for treating major depressive disorder at the Clinical TMS Society Annual Meeting in Chicago. An analysis of real-world data from 1,750 patients supports the efficacy of Deep TMS. The company aims to enhance noninvasive neurostimulation through innovative technologies and research. Alongside depression, BrainsWay's treatment includes indications for obsessive-compulsive disorder and smoking addiction. The company has multiple upcoming presentations at psychiatric conferences throughout May and June 2022.
BrainsWay Ltd. (NASDAQ: BWAY) announced it will report its first-quarter financial results and operational highlights on May 11, 2022, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss the results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders and is known for its FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, with indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
FAQ
What is the current stock price of Brainsway Ltd. (BWAY)?
What is the market cap of Brainsway Ltd. (BWAY)?
